Market capitalization | SEK16.21b |
Enterprise Value | SEK21.39b |
P/E (TTM) P/E ratio | 138.53 |
EV/FCF (TTM) EV/FCF | 31.97 |
EV/Sales (TTM) EV/Sales | 2.14 |
P/S ratio (TTM) P/S ratio | 1.62 |
P/B ratio (TTM) P/B ratio | 3.16 |
Dividend yield | 0.38% |
Last dividend (FY23) | SEK0.50 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
4 Analysts have issued a Addlife forecast:
4 Analysts have issued a Addlife forecast:
Sep '24 |
+/-
%
|
||
Revenue | 10,012 10,012 |
6%
6%
|
|
Gross Profit | 3,735 3,735 |
5%
5%
|
|
EBITDA | 1,529 1,529 |
17%
17%
|
EBIT (Operating Income) EBIT | 599 599 |
16%
16%
|
Net Profit | 117 117 |
60%
60%
|
In millions SEK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AddLife AB engages in the ownership and acquisition of companies in niche segments under the healthcare sector. It operates through the Labtech and Medtech business areas. The Labtech business area provides a range of services in diagnostics, biomedical research, and laboratory analysis. The Medtech business area focuses on publicly funded health, homecare, and social services. The company was founded in 1906 and is headquartered in Stockholm, Sweden.
Head office | Sweden |
CEO | Fredrik Dalborg |
Employees | 2,301 |
Founded | 2014 |
Website | www.add.life |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.